Erasca, Inc. Common Stock (ERAS) News
Latest headlines that mention ERAS, newest first · each headline opens the original publisher
- Last price
- $14.49
- Day change
- -0.89%
- Next earnings
- 2026-11-11
ERAS headlines
latest coverageThis clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.
ERAS news alerts
Get an alert by email or push when a new headline mentions ERAS.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.